Jingli A Zhang
Research Subjects
Research Interests
Jingli A Zhang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Kamb
A2 Biotherapeutics Inc, Agoura Hills, California, USA
2 shared publications - Alexander Partin
A2 Biotherapeutics Inc, Agoura Hills, California, USA
2 shared publications Jushen Liang
A2 Biotherapeutics Inc, Agoura Hills, California, USA
2 shared publicationsRichele Bruno
A2 Biotherapeutics Inc, Agoura Hills, California, USA
2 shared publicationsTimothy P Riley
A2 Biotherapeutics Inc, Agoura Hills, California, USA
2 shared publicationsAaron Winters
A2 Biotherapeutics Inc, Agoura Hills, California, USA
1 shared publication
Latest Publications
- Open Access
- 12 September 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e015068
PLP1-triggered NOT gate to address neurotoxicity risk of PSMA-targeted prostate cancer therapy
Background: On-target, off-tumor toxicity is a recurring challenge for solid tumor therapeutics targeted to antigens preferentially expressed on malignant cells. Prostate-specific membrane antigen (PSMA) is a tumor-associated antigen that is expressed on the healthy prostate and is generally upregulated in prostate cancer. It is also detected via RNA-Seq in the central and peripheral nervous system (CNS and PNS) at levels that can exceed those in the prostate itself. The CNS/PNS expression of PSMA has been largely ignored in the oncology field, and it is possible that therapeutics targeting PSMA have limited access to antigens in the nervous system. However, many PSMA-targeted therapeutics that are active in the clinic induce substantial neurotoxicity, in some cases, even treatment-associated fatalities. Methods: To protect PSMA-expressing neural tissues from on-target, off-tumor toxicity, we applied a synthetic cellular NOT gate that uses a LIR-1-based inhibitory receptor. We selected the NOT gate target antigen by searching genomic databases for a surface protein co-expressed with PSMA in the brain. Results: Here, we demonstrate that proteolipid protein 1 (PLP1), a protein expressed on the surface of oligodendrocytes and Schwann cells, is co-expressed with PSMA in the CNS and PNS. A NOT gate construct (PSMA | PLP1 Tmod) protects human oligodendrocytes in vitro from the cytotoxicity of a PSMA CAR. Though PSMA is not expressed in mouse brains at high levels, we show that PLP1 CARs induce toxicity in mice, consistent with the possibility that CNS/PNS expression of the target of an immunotherapeutic poses a serious risk. This toxicity is mitigated by a Tmod construct (PLP1 | PLP1), in which a PLP1 CAR substitutes for a PSMA CAR, a proof of principle that circumvents the problematic expression pattern of PSMA in the mouse. Conclusions: Together, these findings not only highlight some of the potential risks and benefits of immunotherapy for solid tumors regarding antigens expressed in the brain, but also suggest a specific solution for PSMA CAR-Ts.
- 12 September 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e015068
Open AccessPLP1-triggered NOT gate to address neurotoxicity risk of PSMA-targeted prostate cancer therapy
Background: On-target, off-tumor toxicity is a recurring challenge for solid tumor therapeutics targeted to antigens preferentially expressed on malignant cells. Prostate-specific membrane antigen (PSMA) is a tumor-associated antigen that is expressed on the healthy prostate and is generally upregulated in prostate cancer. It is also detected via RNA-Seq in the central and peripheral nervous system (CNS and PNS) at levels that can exceed those in the prostate itself. The CNS/PNS expression of PSMA has been largely ignored in the oncology field, and it is possible that therapeutics targeting PSMA have limited access to antigens in the nervous system. However, many PSMA-targeted therapeutics that are active in the clinic induce substantial neurotoxicity, in some cases, even treatment-associated fatalities. Methods: To protect PSMA-expressing neural tissues from on-target, off-tumor toxicity, we applied a synthetic cellular NOT gate that uses a LIR-1-based inhibitory receptor. We selected the NOT gate target antigen by searching genomic databases for a surface protein co-expressed with PSMA in the brain. Results: Here, we demonstrate that proteolipid protein 1 (PLP1), a protein expressed on the surface of oligodendrocytes and Schwann cells, is co-expressed with PSMA in the CNS and PNS. A NOT gate construct (PSMA | PLP1 Tmod) protects human oligodendrocytes in vitro from the cytotoxicity of a PSMA CAR. Though PSMA is not expressed in mouse brains at high levels, we show that PLP1 CARs induce toxicity in mice, consistent with the possibility that CNS/PNS expression of the target of an immunotherapeutic poses a serious risk. This toxicity is mitigated by a Tmod construct (PLP1 | PLP1), in which a PLP1 CAR substitutes for a PSMA CAR, a proof of principle that circumvents the problematic expression pattern of PSMA in the mouse. Conclusions: Together, these findings not only highlight some of the potential risks and benefits of immunotherapy for solid tumors regarding antigens expressed in the brain, but also suggest a specific solution for PSMA CAR-Ts.
- Open Access
- 21 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e010976
Onboard, tethered IL-12 boosts potency of the Tmod NOT gate and preserves selectivity
Background: To reach their full potential in cancer therapy, immune cells engineered with synthetic constructs must achieve the challenging dual objectives of potency and selectivity to overcome the key obstacle: non-specific cytotoxicity. These problems are especially challenging for solid tumor therapy, where antigen tissue specificity, accessibility, and tumor microenvironment are problematic. Cells engineered with receptors that act as synthetic logic gates promise to address the issue of tumor specificity by targeting antigen profiles rather than single antigens. Nevertheless, there are limits to the potency benefit that can be achieved at the level of the antigen-targeting receptors. One approach to enhance potency beyond the acute sensitivity of receptor activation is to co-opt a major source of ancillary stimulation in the normal immune response, cytokine receptors. Methods: Enhancing CAR-T efficacy with engineered onboard cytokines, often referred to as “armoring”, is one such approach to boost potency. However, such constructs run the risk of overriding tumor selectivity and eroding the therapeutic window. Here we design and test onboard cytokine constructs that enhance potency and preserve selectivity of a synthetic NOT logic gate construct called Tmod, potentially addressing some of the major challenges in oncology in a single synthetic design. Results: We focused especially on a module encoding membrane-tethered interleukin (IL)-12, a construct that significantly enhances Tmod antigen-dependent long-term proliferation and potency both in vitro and in vivo, without compromising the NOT gate selectivity. Notably, three substantially different in vivo models, including one that employs mouse surrogate antigens, were used to assess preclinical dose-dependent efficacy and safety. Together, these studies make a strong case for the robustness of the design. Conclusions: We conclude that the mem-IL-12 module can be combined with multiple Tmod constructs to boost efficacy and persistence while preserving the on-tumor selectivity.
- 21 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e010976
Open AccessOnboard, tethered IL-12 boosts potency of the Tmod NOT gate and preserves selectivity
Background: To reach their full potential in cancer therapy, immune cells engineered with synthetic constructs must achieve the challenging dual objectives of potency and selectivity to overcome the key obstacle: non-specific cytotoxicity. These problems are especially challenging for solid tumor therapy, where antigen tissue specificity, accessibility, and tumor microenvironment are problematic. Cells engineered with receptors that act as synthetic logic gates promise to address the issue of tumor specificity by targeting antigen profiles rather than single antigens. Nevertheless, there are limits to the potency benefit that can be achieved at the level of the antigen-targeting receptors. One approach to enhance potency beyond the acute sensitivity of receptor activation is to co-opt a major source of ancillary stimulation in the normal immune response, cytokine receptors. Methods: Enhancing CAR-T efficacy with engineered onboard cytokines, often referred to as “armoring”, is one such approach to boost potency. However, such constructs run the risk of overriding tumor selectivity and eroding the therapeutic window. Here we design and test onboard cytokine constructs that enhance potency and preserve selectivity of a synthetic NOT logic gate construct called Tmod, potentially addressing some of the major challenges in oncology in a single synthetic design. Results: We focused especially on a module encoding membrane-tethered interleukin (IL)-12, a construct that significantly enhances Tmod antigen-dependent long-term proliferation and potency both in vitro and in vivo, without compromising the NOT gate selectivity. Notably, three substantially different in vivo models, including one that employs mouse surrogate antigens, were used to assess preclinical dose-dependent efficacy and safety. Together, these studies make a strong case for the robustness of the design. Conclusions: We conclude that the mem-IL-12 module can be combined with multiple Tmod constructs to boost efficacy and persistence while preserving the on-tumor selectivity.